MA33693B1 - Dérivés de pyrazole qui modulent la stéroyl-coa désaturase - Google Patents
Dérivés de pyrazole qui modulent la stéroyl-coa désaturaseInfo
- Publication number
- MA33693B1 MA33693B1 MA34807A MA34807A MA33693B1 MA 33693 B1 MA33693 B1 MA 33693B1 MA 34807 A MA34807 A MA 34807A MA 34807 A MA34807 A MA 34807A MA 33693 B1 MA33693 B1 MA 33693B1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- modulate
- coa
- steroil
- perazol
- Prior art date
Links
- 108010087894 Fatty acid desaturases Proteins 0.000 abstract 2
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention porte sur des dérivés hétérocycliques qui modulent l'activité de la stéaroyl-coa désaturase. L'invention porte également sur des procédés d'utilisation de tels dérivés pour moduler l'activité de la stéaroyl-coa désaturase et sur des compositions pharmaceutiques comprenant de tels dérivés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24763409P | 2009-10-01 | 2009-10-01 | |
PCT/EP2010/064672 WO2011039358A1 (fr) | 2009-10-01 | 2010-10-01 | Dérivés de pyrazole qui modulent la stéaroyl-coa désaturase |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33693B1 true MA33693B1 (fr) | 2012-10-01 |
Family
ID=43066810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34807A MA33693B1 (fr) | 2009-10-01 | 2012-04-26 | Dérivés de pyrazole qui modulent la stéroyl-coa désaturase |
Country Status (22)
Country | Link |
---|---|
US (1) | US20130011361A1 (fr) |
EP (1) | EP2483264A1 (fr) |
JP (1) | JP2013506638A (fr) |
KR (1) | KR20120080226A (fr) |
CN (1) | CN102574841A (fr) |
AU (1) | AU2010302577A1 (fr) |
BR (1) | BR112012007509A2 (fr) |
CA (1) | CA2776294A1 (fr) |
CL (1) | CL2012000797A1 (fr) |
CO (1) | CO6761294A2 (fr) |
CR (1) | CR20120134A (fr) |
EA (1) | EA201200545A1 (fr) |
EC (1) | ECSP12011837A (fr) |
IL (1) | IL218294A0 (fr) |
IN (1) | IN2012DN01913A (fr) |
MA (1) | MA33693B1 (fr) |
MX (1) | MX2012003938A (fr) |
PE (1) | PE20121439A1 (fr) |
SG (1) | SG178869A1 (fr) |
TN (1) | TN2012000085A1 (fr) |
WO (1) | WO2011039358A1 (fr) |
ZA (1) | ZA201201390B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2766000A2 (fr) | 2011-10-15 | 2014-08-20 | F.Hoffmann-La Roche Ag | Procédés d'utilisation d'antagonistes de scd1 |
JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
SG11202009280RA (en) * | 2018-03-23 | 2020-10-29 | Yumanity Therapeutics Inc | Compounds and uses thereof |
GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2225107T3 (es) | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
ATE397625T1 (de) | 1999-09-28 | 2008-06-15 | Bayer Corp | Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung |
DE60142692D1 (de) | 2000-02-24 | 2010-09-09 | Xenon Genetics Inc | Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika |
ATE402262T1 (de) | 2000-09-26 | 2008-08-15 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
BRPI0515483A (pt) * | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
TW200626154A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
WO2007046867A2 (fr) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Derives de piperidine et leurs utilisations comme agents therapeutiques |
KR20130036080A (ko) * | 2006-08-15 | 2013-04-09 | 제논 파마슈티칼스 인크. | 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물 |
BRPI0719122A2 (pt) * | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
CA2662574A1 (fr) * | 2006-09-22 | 2008-03-27 | Novartis Ag | Composes organiques |
US8068738B2 (en) * | 2007-02-21 | 2011-11-29 | Tte Technology, Inc. | System and method for decoding infra-red (IR) signals |
EP2245029B1 (fr) * | 2008-02-20 | 2015-04-15 | Novartis AG | Inhibiteurs hétérocycliques de la stéaroyl-coa désaturase |
-
2010
- 2010-10-01 WO PCT/EP2010/064672 patent/WO2011039358A1/fr active Application Filing
- 2010-10-01 AU AU2010302577A patent/AU2010302577A1/en not_active Abandoned
- 2010-10-01 SG SG2012013066A patent/SG178869A1/en unknown
- 2010-10-01 JP JP2012531447A patent/JP2013506638A/ja active Pending
- 2010-10-01 CN CN201080044452XA patent/CN102574841A/zh active Pending
- 2010-10-01 IN IN1913DEN2012 patent/IN2012DN01913A/en unknown
- 2010-10-01 MX MX2012003938A patent/MX2012003938A/es not_active Application Discontinuation
- 2010-10-01 EA EA201200545A patent/EA201200545A1/ru unknown
- 2010-10-01 PE PE2012000427A patent/PE20121439A1/es not_active Application Discontinuation
- 2010-10-01 KR KR1020127011127A patent/KR20120080226A/ko not_active Application Discontinuation
- 2010-10-01 BR BR112012007509A patent/BR112012007509A2/pt not_active IP Right Cessation
- 2010-10-01 US US13/391,900 patent/US20130011361A1/en not_active Abandoned
- 2010-10-01 CA CA2776294A patent/CA2776294A1/fr not_active Abandoned
- 2010-10-01 EP EP10761003A patent/EP2483264A1/fr not_active Withdrawn
-
2012
- 2012-02-21 TN TNP2012000085A patent/TN2012000085A1/en unknown
- 2012-02-23 IL IL218294A patent/IL218294A0/en unknown
- 2012-02-24 ZA ZA2012/01390A patent/ZA201201390B/en unknown
- 2012-03-20 CR CR20120134A patent/CR20120134A/es unknown
- 2012-03-30 CL CL2012000797A patent/CL2012000797A1/es unknown
- 2012-04-03 CO CO12056222A patent/CO6761294A2/es not_active Application Discontinuation
- 2012-04-26 MA MA34807A patent/MA33693B1/fr unknown
- 2012-04-27 EC ECSP12011837 patent/ECSP12011837A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201200545A1 (ru) | 2012-12-28 |
ZA201201390B (en) | 2012-10-31 |
PE20121439A1 (es) | 2012-11-06 |
MX2012003938A (es) | 2012-08-03 |
JP2013506638A (ja) | 2013-02-28 |
CN102574841A (zh) | 2012-07-11 |
CO6761294A2 (es) | 2013-09-30 |
IL218294A0 (en) | 2012-04-30 |
KR20120080226A (ko) | 2012-07-16 |
ECSP12011837A (es) | 2012-06-29 |
TN2012000085A1 (en) | 2013-09-19 |
EP2483264A1 (fr) | 2012-08-08 |
CR20120134A (es) | 2012-05-17 |
IN2012DN01913A (fr) | 2015-07-24 |
CA2776294A1 (fr) | 2011-04-07 |
BR112012007509A2 (pt) | 2016-11-22 |
CL2012000797A1 (es) | 2013-08-09 |
WO2011039358A1 (fr) | 2011-04-07 |
AU2010302577A1 (en) | 2012-03-15 |
SG178869A1 (en) | 2012-04-27 |
US20130011361A1 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30655B1 (fr) | Composes organiques. | |
MA32150B1 (fr) | Inhibiteurs heterocycliques de la stearoyl-coa desaturase | |
MA31874B1 (fr) | Inhibiteurs de bêta-lactamases | |
MA33693B1 (fr) | Dérivés de pyrazole qui modulent la stéroyl-coa désaturase | |
TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
MA31433B1 (fr) | Inhibiteurs de la p70 s6 kinase | |
MA30945B1 (fr) | Anticorps anti-tat226 et immunoconjugués | |
ATE478072T1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
MX2009006728A (es) | Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd. | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
MA34767B1 (fr) | Compositions et procédés pour la modulation de fxr | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
EA200702128A1 (ru) | Фенильные и пиридильные модуляторы lta4h | |
MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
TW200602330A (en) | Compounds and compositions as PPAR modulators | |
MA33197B1 (fr) | Inhibiteurs de tripeptide époxy cétone protéases cristallines | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
MX2009003080A (es) | Compuestos organicos heterociclicos. | |
MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
MA33323B1 (fr) | Thérapie adjuvante de cancer | |
UA83917C2 (en) | 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors | |
TW200600505A (en) | Compounds and compositions as ppar modulators |